MarketCapExport financials
Celcuity (CELC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Celcuity Balance Sheet 2025-2011 | CELC
Brief overview of Celcuity 's assets and capital
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Total assets increased by +443.1%, from $85.9 million to $466.6 million. A CAGR near 52.7% points to substantial expansion.
Liabilities grew faster than assets: +2,028.4% versus +443.1%. A substantial part of expansion was externally funded.
The equity ratio equals 21.6%, with a starting level of 80%. Stable cash flow is important under this structure.
Net debt moved below zero to -$28.1 million, reflecting surplus cash over debt.
The cash share moved from 98.1% to 35.5%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$448.9 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
The balance sheet gives no single signal for Celcuity : some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet Celcuity
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-28.1 M | 82.8 M | 7.09 M | 11.4 M | -68.1 M | -11.4 M | -18.5 M | -15.9 M | -2.64 M | -5.86 M | -5.07 M | - | - | - | - |
Long Term Debt |
138 M | 105 M | 37.6 M | 35.8 M | 16 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
54 K | 172 K | 185 K | 192 K | 190 K | 188 K | 178 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
322 M | 97.8 M | 37.3 M | 35 M | 14.7 M | 69.2 K | 71.9 K | 19.9 K | - | - | - | - | - | - | - |
Total Current Liabilities |
44.2 M | 31.7 M | 14.2 M | 6.88 M | 2.51 M | 1.19 M | 911 K | 662 K | 578 K | - | - | - | - | - | - |
Total Liabilities |
366 M | 130 M | 51.5 M | 41.9 M | 17.2 M | 1.25 M | 983 K | 682 K | 578 K | 445 K | 284 K | - | - | - | - |
Retained Earnings |
-449 M | -272 M | -160 M | -96.3 M | -55.9 M | -26.3 M | -16.8 M | -9.49 M | -2.01 M | -8.33 M | -5.02 M | - | - | - | - |
Total Assets |
467 M | 245 M | 191 M | 176 M | 85.9 M | 13 M | 20.3 M | 26 M | 32 M | 6.06 M | 5.3 M | - | - | - | - |
Cash and Cash Equivalents |
166 M | 22.5 M | 30.7 M | 24.6 M | 84.3 M | 11.6 M | 18.7 M | 15.9 M | 2.64 M | - | - | - | - | - | - |
Book Value |
101 M | 116 M | 140 M | 134 M | 68.7 M | 11.7 M | 19.3 M | 25.3 M | 31.4 M | 5.61 M | 5.02 M | - | - | - | - |
Total Shareholders Equity |
101 M | 116 M | 140 M | 134 M | 68.7 M | 11.7 M | 19.3 M | 25.3 M | 31.4 M | 5.61 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Celcuity
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
848 K | 893 K | 196 M | 195 M | 195 M | 106 M | 13 K | 54 K | 95.7 K | 139 K | 182 K | 226 K | 271 K | 317 K | 364 K | 61 K | 108 K | 16.2 M | 15.3 K | 61.8 K | 109 K | 15.8 M | 6.84 K | 60.9 K | 107 K | 8.3 K | 12.7 K | 57.8 K | 102 K | 146 K | 177 K | 19.9 K | 19.9 K | 19.9 K | 19.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
755 M | 754 M | 323 M | 322 M | 320 M | 99.3 M | 98.5 M | 97.8 M | 97 M | 96.3 M | 37.7 M | 37.3 M | 36.8 M | 36.3 M | 35.8 M | 35 M | 15.1 M | 15 M | 14.8 M | 14.7 M | 14.5 M | 14.2 M | - | 69.2 K | 117 K | 11.2 K | - | 71.9 K | 117 K | 163 K | 195 K | 19.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
801 M | 841 M | 357 M | 366 M | 359 M | 139 M | 131 M | 130 M | 123 M | 116 M | 54.4 M | 51.5 M | 49.5 M | 43.4 M | 41.6 M | 41.9 M | 21.8 M | 19.2 M | 18.4 M | 17.2 M | 17.4 M | 15.8 M | 1.19 M | 1.25 M | 1.15 M | 840 K | 878 K | 983 K | 1.03 M | 1.05 M | 1.08 M | 682 K | 682 K | 682 K | 682 K | 578 K | 336 K | 578 K | 578 K | 445 K | 445 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-654 M | -581 M | -502 M | -449 M | -398 M | -354 M | -309 M | -272 M | -235 M | -205 M | -182 M | -160 M | -141 M | -123 M | -108 M | -96.3 M | -84.7 M | -73.8 M | -63.9 M | -55.9 M | -49.2 M | -43.1 M | -29.1 M | -26.3 M | -23.8 M | -21.3 M | -19.1 M | -16.8 M | -15 M | -13.1 M | -11.3 M | -9.49 M | -9.49 M | -9.49 M | -9.49 M | -2.01 M | -283 K | -2.01 M | -2.01 M | -8.33 M | -8.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
727 M | 828 M | 410 M | 467 M | 476 M | 184 M | 218 M | 245 M | 273 M | 293 M | 188 M | 191 M | 142 M | 154 M | 165 M | 176 M | 65.3 M | 72.4 M | 79.9 M | 85.9 M | 91.8 M | 42.8 M | 36.4 M | 13 M | 14.9 M | 16.7 M | 18.4 M | 20.3 M | 21.7 M | 23.4 M | 24.9 M | 26 M | 26 M | 26 M | 26 M | 32 M | 33.1 M | 32 M | 32 M | 6.06 M | 6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
178 M | 182 M | 145 M | 166 M | 74.3 M | 46.4 M | 16.5 M | 22.5 M | 12.6 M | 30.5 M | 31.2 M | 30.7 M | 25.8 M | 32.2 M | 33.6 M | 24.6 M | 57.5 M | 66.9 M | 78.3 M | 84.3 M | 90.4 M | 41.6 M | 34.9 M | 11.6 M | 13.7 M | 15.4 M | 16.9 M | 18.7 M | 16.3 M | 14.9 M | 14.7 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 2.69 M | 32.4 M | 2.64 M | 2.64 M | 5.86 M | 5.86 M | - | - | 5.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-74 M | -12.8 M | 53.5 M | 101 M | 117 M | 44.4 M | 86.7 M | 116 M | 150 M | 177 M | 134 M | 140 M | 92.9 M | 110 M | 123 M | 134 M | 43.5 M | 53.2 M | 61.5 M | 68.7 M | 74.5 M | 27 M | 35.2 M | 11.7 M | 13.8 M | 15.9 M | 17.5 M | 19.3 M | 20.7 M | 22.4 M | 23.9 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 31.4 M | 32.8 M | 31.4 M | 31.4 M | 5.61 M | 5.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-74 M | -12.8 M | 53.5 M | 101 M | 117 M | 44.4 M | 86.7 M | 116 M | 150 M | 177 M | 134 M | 140 M | 92.9 M | 110 M | 123 M | 134 M | 43.5 M | 53.2 M | 61.5 M | 68.7 M | 74.5 M | 27 M | 35.2 M | 11.7 M | 13.8 M | 15.9 M | 17.5 M | 19.3 M | 20.7 M | 22.4 M | 23.9 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 31.4 M | 32.8 M | 31.4 M | 31.4 M | 5.61 M | 5.61 M | - | - | 5.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Celcuity , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |